Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H44O9 |
| Molecular Weight | 548.665 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 13 / 13 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@@H]1[C@@H](O)[C@H](C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]5(C)[C@H](CC[C@]45O)C6=CC(=O)OC6)C2)[C@H]1O
InChI
InChIKey=PMTSPAGBAFCORP-HBUONDEYSA-N
InChI=1S/C30H44O9/c1-16-24(33)26(36-3)25(34)27(38-16)39-19-6-10-29(15-31)18(13-19)4-5-22-21(29)7-9-28(2)20(8-11-30(22,28)35)17-12-23(32)37-14-17/h12,15-16,18-22,24-27,33-35H,4-11,13-14H2,1-3H3/t16-,18+,19-,20+,21-,22+,24-,25-,26+,27-,28+,29+,30-/m0/s1
| Molecular Formula | C30H44O9 |
| Molecular Weight | 548.665 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 13 / 13 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27110755
https://www.ncbi.nlm.nih.gov/pubmed/22396588
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27110755
https://www.ncbi.nlm.nih.gov/pubmed/22396588
Peruvoside, main component of neriperside, a tevetoside extracted from Thevitia neriifolia Juss, cardiac glycoside, is used for the treatment of heart failure. It is Na+, K(+)-ATPase inhibitor. Peruvoside also demonstrates anti-cancer activities. Peruvoside inhibited cell growth in androgen-resistant LNCaP-abl prostate at 50 nM, lower than the concentrations required by both Digoxin and Strophanthidin (500 nM), suggesting that it may be a more potent anti-cancer candidate that other CGs. Peruvoside induced apoptotic cell death in human primitive AML KG1a cells and chronic myelogenous leukemia (CML) cell K562.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL385 |
75.0 µM [IC50] | ||
Target ID: Sodium:potassium-exchanging ATPase activity |
0.18 µM [IC50] | ||
Target ID: CHEMBL396 |
45.0 nM [IC50] | ||
Target ID: CHEMBL1871 |
10.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Encordin Approved UseCardiac disorders |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Interaction of digitalis-like compounds with p-glycoprotein. | 2013-02 |
|
| Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. | 2009-04-01 |
|
| A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor. | 2004-02-15 |
|
| Myasthenia-like syndrome induced by cardiovascular agents. Report of a case. | 1987-04 |
Patents
Sample Use Guides
Congattve Heart Failure :The average effective dose was 2.4 mg. (1.8 to 3.2 mg.) followed by a maintenance dose of 0.6 mg (0.3 to 0.9 mg.).
Route of Administration:
Intra-arterial
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:30:58 GMT 2025
by
admin
on
Mon Mar 31 22:30:58 GMT 2025
|
| Record UNII |
CT36KGC6A6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
C01AX02
Created by
admin on Mon Mar 31 22:30:58 GMT 2025 , Edited by admin on Mon Mar 31 22:30:58 GMT 2025
|
||
|
WHO-VATC |
QC01AX02
Created by
admin on Mon Mar 31 22:30:58 GMT 2025 , Edited by admin on Mon Mar 31 22:30:58 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3809
Created by
admin on Mon Mar 31 22:30:58 GMT 2025 , Edited by admin on Mon Mar 31 22:30:58 GMT 2025
|
PRIMARY | |||
|
CT36KGC6A6
Created by
admin on Mon Mar 31 22:30:58 GMT 2025 , Edited by admin on Mon Mar 31 22:30:58 GMT 2025
|
PRIMARY | |||
|
SUB14819MIG
Created by
admin on Mon Mar 31 22:30:58 GMT 2025 , Edited by admin on Mon Mar 31 22:30:58 GMT 2025
|
PRIMARY | |||
|
12314120
Created by
admin on Mon Mar 31 22:30:58 GMT 2025 , Edited by admin on Mon Mar 31 22:30:58 GMT 2025
|
PRIMARY | |||
|
DTXSID70881388
Created by
admin on Mon Mar 31 22:30:58 GMT 2025 , Edited by admin on Mon Mar 31 22:30:58 GMT 2025
|
PRIMARY | |||
|
m392
Created by
admin on Mon Mar 31 22:30:58 GMT 2025 , Edited by admin on Mon Mar 31 22:30:58 GMT 2025
|
PRIMARY | Merck Index | ||
|
PERUVOSIDE
Created by
admin on Mon Mar 31 22:30:58 GMT 2025 , Edited by admin on Mon Mar 31 22:30:58 GMT 2025
|
PRIMARY | |||
|
DB13756
Created by
admin on Mon Mar 31 22:30:58 GMT 2025 , Edited by admin on Mon Mar 31 22:30:58 GMT 2025
|
PRIMARY | |||
|
1182-87-2
Created by
admin on Mon Mar 31 22:30:58 GMT 2025 , Edited by admin on Mon Mar 31 22:30:58 GMT 2025
|
PRIMARY | |||
|
214-659-9
Created by
admin on Mon Mar 31 22:30:58 GMT 2025 , Edited by admin on Mon Mar 31 22:30:58 GMT 2025
|
PRIMARY | |||
|
100000079423
Created by
admin on Mon Mar 31 22:30:58 GMT 2025 , Edited by admin on Mon Mar 31 22:30:58 GMT 2025
|
PRIMARY | |||
|
CHEMBL1075790
Created by
admin on Mon Mar 31 22:30:58 GMT 2025 , Edited by admin on Mon Mar 31 22:30:58 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
